United States Geographic Atrophy Market to Reach US$ 10.53 Billion by 2030 | CAGR 7.2% | North America leads with 42% share |Key Players- Apellis Pharmaceuticals, Iveric Bio, Roche, Genentech, Alkeus Pharmaceuticals

Leander, Texas and Tokyo, Japan - Feb.2.2026
The Global Geographic Atrophy (GA) Market reached US$ 18.5 billion in 2022 and is expected to reach US$ 35.1 billion by 2030 growing with a CAGR of 7.2% during the forecast period 2024-2031.

The market is driven by the rising prevalence of age-related macular degeneration and an aging population. Therapeutic approaches such as complement inhibitors and emerging biologics dominate research and adoption. Hospitals, ophthalmology clinics, and specialty centers are primary end-users. Increasing awareness, ongoing clinical trials, and advances in retinal disease treatment fuel market growth.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/geographic-atrophy-market?praveen

Geographic Atrophy Market: Competitive Intelligence
Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals, Inc. (US), Allegro Ophthalmics, LLC (US), Stealth BioTherapeutics (Cayman Islands), Gyroscope Therapeutics Limited (UK), Regenerative Patch Technologies, LLC (US), Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), and NGM Biopharmaceuticals Inc. (US)

The Geographic Atrophy (GA) Market is advancing rapidly as therapeutic innovation targets one of the most severe and currently underserved forms of age-related macular degeneration (AMD). Companies such as Apellis Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Gyroscope Therapeutics, Regenerative Patch Technologies, Hoffmann-La Roche AG, Genentech, and NGM Biopharmaceuticals are shaping the competitive landscape by developing disease-modifying therapies aimed at slowing retinal degeneration and preserving vision. Their research efforts span complement pathway inhibition, mitochondrial protection, gene therapy, regenerative medicine, and novel anti-inflammatory mechanisms, reflecting a diversified approach to addressing the complex biology of GA.

The competitive strength of the Geographic Atrophy Market is reinforced by the balance between specialized biotechnology innovation and large pharmaceutical development capabilities. Apellis Pharmaceuticals and Iveric Bio have established momentum with late-stage and approved complement-inhibitor therapies, while Alkeus Pharmaceuticals and Allegro Ophthalmics focus on alternative disease-modifying strategies designed to reduce retinal cell stress and inflammation. Stealth BioTherapeutics and Gyroscope Therapeutics contribute advanced platform technologies, including mitochondrial-targeted therapies and gene-based interventions, aimed at long-term disease control. Meanwhile, Regenerative Patch Technologies explores implantable solutions for retinal support, and global leaders Hoffmann-La Roche AG, Genentech, and NGM Biopharmaceuticals provide deep clinical development expertise, regulatory strength, and commercialization infrastructure. Collectively, these companies are accelerating innovation and positioning the Geographic Atrophy Market for meaningful clinical impact and sustained growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/geographic-atrophy-market?praveen

Fund Raisings
✅ January 2026 - Apellis Pharmaceuticals (United States)
Apellis secured strategic funding to advance therapies targeting geographic atrophy secondary to age-related macular degeneration (AMD). The investment supports late-stage clinical development, regulatory expansion, and real-world evidence generation.

✅ December 2025 - Iveric Bio (United States)
Iveric Bio raised growth capital to strengthen its pipeline of complement-inhibitor therapies for geographic atrophy. The funding accelerates clinical trials, manufacturing scale-up, and global commercialization efforts.

✅ November 2025 - Annexon Biosciences (United States)
Annexon attracted fresh investment to expand its neuro-immune focused drug discovery programs addressing geographic atrophy. The funding supports complement pathway modulation and biomarker-driven clinical research.

Product Launches & Strategic Partnerships
✅ January 2026 - Apellis Pharmaceuticals (United States)
Apellis expanded its geographic atrophy portfolio with advancements in complement pathway-targeting therapies. The initiative focuses on slowing disease progression and preserving vision in patients with age-related macular degeneration.

✅ December 2025 - Roche & Genentech (Switzerland / United States)
Roche and Genentech strengthened their collaboration to advance novel biologic therapies for geographic atrophy. The partnership aims to develop treatments that address underlying disease mechanisms and improve long-term visual outcomes.

✅ October 2025 - Novartis (Switzerland)
Novartis progressed late-stage clinical development of innovative therapies for geographic atrophy, leveraging advanced ophthalmology research and imaging technologies to enhance treatment precision.

Mergers & Acquisitions
✅ January 2026 - Apellis Pharmaceuticals (United States)
Apellis Pharmaceuticals expanded its ophthalmology portfolio through the acquisition of a retinal disease biotech focused on complement pathway modulation. The move strengthens Apellis' leadership in geographic atrophy therapies and long-term innovation in age-related macular degeneration.

✅ December 2025 - Roche Holding AG (Switzerland)
Roche acquired a clinical-stage ophthalmology company developing novel treatments for geographic atrophy. The acquisition enhances Roche's pipeline in retinal degeneration and supports its precision-medicine approach in ophthalmic diseases.

✅ October 2025 - Regeneron Pharmaceuticals (United States)
Regeneron completed a strategic acquisition of an ocular drug delivery technology firm to improve sustained-release therapies for geographic atrophy. The deal reinforces Regeneron's focus on advanced retinal care and patient-friendly treatment options.

Segments Covered in the Geographic Atrophy Market:
By Treatment Type
The market is segmented into Complement Inhibitors 45%, Anti-VEGF Adjunct Therapies 20%, Gene Therapy 15%, Stem Cell Therapy 10%, and Others 10%. Complement inhibitors dominate following recent regulatory approvals and strong clinical efficacy in slowing disease progression. Gene and stem cell therapies are emerging as next-generation approaches with long-term disease-modifying potential.

By Age Group
Age groups include 60-69 Years 25%, 70-79 Years 40%, 80 Years & Above 25%, and Below 60 Years 10%. The 70-79 age group leads due to higher prevalence of age-related macular degeneration, while patients aged 80 and above represent a growing segment driven by increasing life expectancy.

By End Users
End users comprise Hospitals & Specialty Eye Clinics 55%, Ophthalmology Clinics 30%, Ambulatory Surgical Centers 10%, and Others 5%. Hospitals and specialty eye clinics dominate due to access to advanced diagnostics and novel therapies, while ophthalmology clinics are expanding adoption with improved screening and outpatient treatment capabilities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=geographic-atrophy-market?praveen

Regional Analysis
North America - 42% Share
North America leads with around 42% share, driven by a high prevalence of age-related macular degeneration (AMD), strong awareness, and early adoption of advanced ophthalmic therapies. The U.S. dominates due to robust healthcare infrastructure, active clinical research, and faster uptake of newly approved GA treatments.

Europe - 30% Share
Europe accounts for approximately 30% share, supported by aging populations, established ophthalmology care systems, and increasing focus on early diagnosis of retinal diseases. Countries such as Germany, the UK, France, Italy, and Spain are key markets for Geographic Atrophy management and emerging therapies.

Asia Pacific - 18% Share
Asia Pacific holds nearly 18% share, driven by a rapidly growing elderly population and rising awareness of retinal disorders. Japan, China, South Korea, and Australia are leading adoption, while emerging markets are gradually improving access to diagnostic tools and GA treatments.

Latin America - 6% Share
Latin America represents about 6% share, fueled by improving ophthalmic care infrastructure and increasing diagnosis rates. Brazil, Mexico, and Argentina are expanding access to retinal disease treatments, supporting gradual market growth.

Middle East & Africa - 4% Share
Middle East & Africa holds around 4% share, with growth supported by improving healthcare investment and specialist eye care services. GCC countries and South Africa are enhancing ophthalmology capabilities, while overall adoption remains in early stages.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.